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OBJECTIVES We determined whether statin use (vs. non-use) is associated with less annual decline in
lower-extremity functioning in patients with and without lower-extremity peripheral arterial
disease (PAD) over three-year follow-up.
BACKGROUND It is unclear whether statin use is associated with less functional decline in patients with PAD.
METHODS Participants included 332 men and women with an ankle brachial index (ABI)0.90 and 212
with ABI 0.90 to 1.50. Functional outcomes included 6-min walk distance and usual and
rapid-pace 4-m walking velocity. A summary performance score combined performance in
walking speed, standing balance, and time for five repeated chair rises into an ordinal score
ranging from 0 to 12 (12  best).
RESULTS Adjusting for age, race, gender, comorbidities, education, health insurance, total cholesterol/
high-density lipoprotein level, body mass index, pack-years of smoking, leg symptoms,
immediately previous year functioning, statin use/non-use, ABI, and change in ABI, the
PAD participants using statins had less annual decline in usual-pace walking velocity (0.002
vs. 0.024 m/s/year, p  0.013), rapid-pace walking velocity (0.006 vs. 0.042 m/s/year,
p  0.006), 6-min walk performance (34.5 vs. 57.9 feet/year, p  0.088), and the
summary performance score (0.152 vs. 0.376, p  0.067) compared with non-users.
These associations were attenuated slightly by additional adjustment for high-sensitivity
C-reactive protein levels. Among non-PAD participants, there were no significant associa-
tions between statin use and functional decline.
CONCLUSIONS The PAD patients on statins have less annual decline in lower-extremity performance than
PAD patients who are not taking statins. (J Am Coll Cardiol 2006;47:998–1004) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.052by the American College of Cardiology Foundation
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g-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
rugs (statins) have beneficial effects on atherosclerosis over
nd above modification of the lipid profile. These include
eduction of vascular inflammation, atheromatous plaque sta-
ilization, and increases in nitric oxide concentrations leading
o greater endothelium-dependent vasodilation (1–4). Such
roperties may contribute to reductions in cardiac and cere-
rovascular events in patients taking statins (5–7).
In cross-sectional analyses, men and women with lower-
xtremity peripheral arterial disease (PAD) have impaired
unctioning proportionate to the PAD severity, as measured
y the ankle-brachial index (ABI), compared with those
ithout PAD (8). A previous cross-sectional study showed
tatin users with PAD to have less functional impairment
han statin non-users (9). Recent clinical trials have shown
ixed results regarding treadmill walking performance
mong PAD patients with intermittent claudication taking
tatins compared with those not taking statins (10–12). To
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ccepted October 7, 2005.ur knowledge, no prior studies have described associations
etween statin use and annual decline in objectively assessed
unctional outcome measures in a large group of patients
ith PAD, including those with and without classic symp-
oms of intermittent claudication. In a three-year prospec-
ive study of men and women with and without PAD, we
ypothesized that statin use would be associated with less
nnual functional decline than statin non-use in patients
ith and without PAD.
ETHODS
ethods for this longitudinal study of functional outcomes
n men and women with and without PAD have been
eported previously and are summarized here (13).
articipant identification. The protocol was Institutional
eview Board-approved by Northwestern University Fein-
erg School of Medicine and Catholic Health Partners
ospitals. Participants gave informed consent. The PAD
articipants were identified consecutively from patients
iagnosed with PAD in three Chicago-area non-invasive
ascular laboratories. Non-PAD participants were identified
onsecutively from patients with normal lower-extremity
rterial studies in three Chicago-area non-invasive vascular
aboratories and from patients with appointments in a large
eneral medicine practice at Northwestern University. Non-
AD participants were identified from the general medicine
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March 7, 2006:998–1004 Statins and Functional Declineractice because these individuals are comparable to patients
ithout PAD who are typically encountered in general
edical practice. Non-PAD participants were identified
rom the non-invasive vascular laboratory because these
ndividuals were expected to more closely resemble the PAD
opulation (i.e., with regard to leg symptoms and demo-
raphics) except for the presence versus absence of PAD.
Identified individuals were invited to return to the med-
cal center for a baseline study visit between October 1998
nd January 2000. Participants were asked to return annu-
lly for follow-up.
xclusion criteria. Presence of PAD was defined as ABI
0.90. Absence of PAD was defined as ABI 0.90 and
1.50 (8). Individuals with ABI 1.50 were excluded
ecause this indicates poorly compressible leg arteries and
nability to gauge arterial perfusion accurately (14).
Individuals with PAD diagnosed in the non-invasive
ascular laboratory were excluded if their study visit ABI
ndicated an absence of PAD. This occasionally occurred
hen PAD participants were revascularized between vascu-
ar laboratory testing and their study visit. It also occurred in
ndividuals with borderline ABI values of approximately
.90 because of measurement variation. Patients with de-
entia were excluded because of the inability to answer
uestions accurately. Nursing home residents, wheelchair-
ound patients, and patients with foot or leg amputations
ere excluded because they were unable to perform many of
he functional measures. Non–English-speaking patients
ere excluded because investigators were not fluent in
on-English languages. Patients with recent major surgery
ere excluded. Participants with a normal ABI and a history
f prior lower-extremity revascularization were excluded
ecause these individuals could not be clearly classified as
on-PAD participants, yet did not meet our inclusion
riterion for PAD participants. The PAD participants who
nderwent lower-extremity revascularization after baseline
ere excluded because the revascularization may have al-
ered their functional decline, independent of statin use
ersus non-use.
nkle brachial index measurement. The ABI was mea-
ured using established methods (8,14). After participants
ested supine for five minutes, a hand-held Doppler probe
Nicolet Vascular Pocket Dop II, Golden, Colorado) was
sed to measure systolic pressures in the right brachial
rtery, right dorsalis pedis and posterior tibial arteries, left
orsalis pedis and posterior tibial arteries, and left brachial
rtery. Each pressure was measured twice: in the order listed
Abbreviations and Acronyms
ABI  ankle-brachial index
BMI  body mass index
HDL  high-density lipoprotein
hsCRP  high-sensitivity C-reactive protein
PAD  peripheral arterial diseasend then in the reverse order. The ABI was calculated in dach leg by dividing average pressures in each leg by the
verage of the four brachial pressures. Average brachial
ressures in the arm with the highest pressure were used
hen one brachial pressure was higher than the opposite
rachial pressure in both measurement sets and the two
rachial pressures differed by 10 mm Hg in at least one
easurement set, because in such cases subclavian stenosis
as possible (14). The lowest leg ABI was used in analyses.
igh-sensitivity C-reactive protein levels. High-sensitivity
-reactive protein (hsCRP) levels were determined using an
mmunotechnique on the Behring BN II analyzer (Dade
ehring, Wilmington, Delaware) (15).
holesterol levels. Total cholesterol levels were measured
sing enzymatic reaction with peroxidase/phenol-4-
minoiphenazone indicator reaction (16). High-density li-
oprotein (HDL) cholesterol was measured using a direct
nzymatic colorimetric assay (17).
omorbidities. Algorithms developed for the Women’s
ealth and Aging Study and the Cardiovascular Health
tudy were used to document comorbidities (18). These
lgorithms combine data from patient reports, physical
xaminations, medical record reviews, medications, labora-
ory values, and a primary care physician questionnaire.
merican College of Rheumatology criteria were used to
iagnose knee and hip osteoarthritis (19,20). Comorbidities
ssessed were angina, diabetes mellitus, myocardial infarc-
ion, stroke, heart failure, pulmonary disease, knee and hip
rthritis, spinal stenosis, disk disease, Parkinson disease, and
ip fracture. These comorbidities were chosen because they
re associated with impaired functioning (21,22).
tatin use. All prescription and over-the-counter medica-
ions were recorded at each study visit. Doses were not
ecorded. The study principal investigator (M.M.M.) iden-
ified statin medications from all recorded medications
hile blinded to all other participant data.
unctional measures. Functional measures were per-
ormed at baseline and at each follow-up visit by a health
nterviewer blinded to the ABI value. Our primary outcome
easure was the 6-min walk test.
-min walk. Following a standardized protocol (23), par-
icipants walked up and down a 100-foot hallway for six
inutes after instructions to cover as much distance as
ossible.
ummary performance score. The summary performance
core is a global measure of lower-extremity functioning
hat predicts mobility loss, nursing home placement, and
ortality among community-dwelling older men and
omen (24–27). To calculate the summary performance
core, a 0 to 4 score is assigned for performance on 4-m
alking velocity, time to rise from a seated position five
imes, and standing balance, respectively (24–27). Individ-
als receive a 0 score for each task they are unable to
omplete. Scores of 1 to 4 for each task are assigned based
n quartiles of performance for over 5,000 community-
welling men and women (24–27). Scores are summed to
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Statins and Functional Decline March 7, 2006:998–1004btain the summary performance score, ranging from
to 12.
epeated chair rises. Participants sat in a straight-backed
hair with arms folded across their chest and stood five
imes consecutively as quickly as possible. The time for five
hair rises was measured.
tanding balance. Participants were asked to hold three
ncreasingly difficult standing positions for 10 s each: stand-
ng with both feet together side-by-side and parallel (side-
y-side stand), standing feet parallel with the toes of one
oot adjacent to and touching the heel of the opposite foot
semi-tandem stand), and standing with one foot directly in
ront of the other (tandem stand) (24–27).
he 4-m walking velocity. Walking velocity was measured
ith a 4-m walk performed at “usual” and “fastest” pace.
ach walk was performed twice. The faster walk in each pair
as used in analyses (24–27).
ther measures. Height and weight were measured at the
aseline and follow-up visits. Body mass index (BMI) was
alculated as weight (kg)/height (m)2. Pack-years of ciga-
ette smoking, education level, and type of medical insur-
nce were determined based on patient report.
ollow-up. Some participants who returned for follow-up
esting refused to complete functional assessments. In these
nstances, we used the following a priori defined criteria to
etermine whether these participants were too disabled to
omplete functional measures. First, individuals for whom
ata collection forms indicated that the participant was
nable to complete functional measures because of wheel-
hair confinement, exhaustion, shortness of breath, or other
ignificant symptom were considered too disabled to com-
lete functional measures. The study principal investigator
M. M. M.) made these decisions from information on the
ata collection forms, blinded to participant characteristics
ncluding ABI, PAD status, and functional performance at
aseline. When data collection forms provided no informa-
ion on the reason(s) that an individual refused to walk, a
riori criteria were used to determine whether the partici-
ant was likely to have been too disabled to walk. These
riteria were: 1) the participant reported walking fewer than
ve blocks during the previous week; 2) the score for
epeated chair rises equaled 0 or 1; 3) the score for the
tanding balance test equaled 0 or 1. Participants who did
ot complete functional assessments and met two of these
hree criteria were considered too disabled to walk. Partic-
pants classified as too disabled to complete functional
ssessments were assigned the minimum value of perfor-
ance for each test that they did not complete. The
inimum value for each test was equivalent to the poorest
erformance among those who completed testing.
tatistical analyses. Baseline characteristics of participants
ere expressed according to their group classification (base-
ine statin use vs. baseline non-use) as means (SD) for
ontinuous variables and proportions for binary variables
Table 1). The test for comparing the baseline statin users
nd non-users was performed using a two-sample t test for tontinuous variables and a chi-square test for binary
ariables.
In comparing functional performance across the time-
ependent variable statin use versus non-use, a longitudinal
r repeated measures analysis of covariance was carried out
sing mixed linear regression models (28). The subject-
pecific random effect was used to accommodate the likely
orrelation between repeated measurements for the same
articipant. The primary dependent variable for each anal-
sis was the successive difference in the particular functional
erformance measure of interest (from baseline to year 1,
rom year 1 to year 2, and from year 2 to year 3). The
nalyses were performed in two steps. The independent
ariables in the first model include baseline covariates
gender, age, race, comorbidities, education, and health
nsurance) and time-dependent covariates (immediately
revious year functioning and ABI, annual change in ABI,
urrent year BMI, leg symptom, pack-years of smoking, and
tatin use). The time-dependent covariate changes over
ime for the same participants, e.g., statin use at year 1,
, and 3, are covariate values for successive changes in
unctional performances from baseline to year 1, from
ear 1 to year 2, and from year 2 to year 3, respectively.
he fully adjusted analyses were also adjusted for total
holesterol at baseline, annual hsCRP level, and other
ardiovascular medication use.
Under mixed effects linear models, statistically valid
nference is guaranteed provided any missing data caused by
atient dropout are unrelated to observed or unobserved
ata (i.e., any missing data are missing at random). As a
afeguard against violations to this assumption, we repeated
he fully adjusted comparisons of functional performance
etween groups using a repeated measures pattern-mixture
nalysis of covariance model (29,30). These analyses yielded
imilar results to those of our primary analyses.
ESULTS
f 641 patients who completed all baseline testing, 544
84.9%) completed at least one follow-up visit and were
ncluded in analyses. The mean time between annual
ollow-up visits for all participants was 12.4 months (SD 
.4). Table 1 shows baseline characteristics of participants
ccording to presence versus absence of PAD and statin
se/non-use at baseline. Among PAD and non-PAD par-
icipants combined, statin users had significantly lower
BIs and total cholesterol levels, higher BMIs, and higher
revalences of cardiac and cerebrovascular disease compared
ith non-users. Statin users included more college gradu-
tes. Of 332 patients with PAD, 69 (20.7%) discontinued
tatins, and a total of 52 (15.7%) were newly initiated on
tatins over the three-year follow-up period. Of 212 patients
n the non-PAD group, 29 (13.7%) discontinued statins,
nd 24 (11.3%) were newly initiated on them over the
hree-year follow-up period. At baseline, nine of the non-
Table 1. Baseline Characteristics of Participants With and Without Peripheral Arterial Disease According to Presence Versus Absence of Statin Use
PAD
N  332
Non-PAD
N  212
All Participants
N  544
Statin Users
(n  152)
Non-Users
(n  180)
Statin Users
(n  61)
Non-Users
(n  151)
Statin Users
(n  213)
Non-Users
(n  331)
Age (yrs) 70.9 (7.7) 72.1 (9.1) 69.2 (7.5) 69.6 (8.3) 70.5 (7.7) 70.9 (8.8)
Male (%) 64.5 60.0 55.7 49.7 62.0 55.3
African-American race (%) 12.5 14.4 16.4 17.2 13.6 15.7
Ankle-brachial index 0.66 (0.14) 0.64 (0.15) 1.08 (0.10) 1.11 (0.12) 0.78 (0.23)* 0.86 (0.27)
Body mass index 27.5 (4.5)† 25.9 (6.3) 28.2 (5.4) 27.5 (6.5) 27.7 (4.8)‡ 26.6 (6.4)
Total cholesterol (mg/dl) 171 (37.6)§ 188 (37.4) 165 (32.3) 182 (38.1) 169 (36.1)§ 186 (37.8)
Ratio of total cholesterol/HDL 4.75 (2.02)‡ 5.19 (1.67) 4.09 (1.29) 4.41 (1.73) 4.56 (1.86) 4.83 (1.74)
Smoking (pack years) 37.6 (33.2) 38.6 (34.2) 13.4 (23.6) 19.6 (27.6) 30.7 (32.6) 30.0 (32.7)
Diabetes (%) 30.9 33.3 18.0 18.5 27.2 26.6
Heart disease and stroke (%) 69.7§ 47.8 55.7¶ 28.5 65.7§ 39.0
Health insurance
Medicare  private (%) 48.7 55.0 45.9 34.4 47.9 45.6
Medicare (%) 25.7 18.3 21.3 24.5 24.4 21.1
Public aid/Medicaid/no health insurance (%) 3.3 6.7 4.9 7.9 3.8 7.2
Education: college graduate or higher (%) 46.7# 35.6 50.8 40.0 47.9** 37.6
Functional performance
6-min walk distance (ft) 1184 (361) 1116 (375) 1466 (442) 1408 (446) 1264 (406) 1249 (433)
Normal-pace 4-m walking velocity (m/s) 0.915 (0.179)†† 0.869 (0.228) 0.990 (0.192) 0.941 (0.216) 0.937 (0.185) 0.902 (0.225)
Normal-pace 4-m walking time (s) 4.55 (1.00)‡‡ 5.05 (2.08) 4.23 (1.09) 4.61 (1.79) 4.46 (1.03)§§ 4.85 (1.96)
Rapid-pace 4-m walking velocity (m/s) 1.258 (0.231)  1.184 (0.297) 1.316 (0.262) 1.287 (0.304) 1.275 (0.241) 1.231 (0.304)
Rapid-pace 4-m walking time (s) 3.31 (0.76)¶¶ 3.70 (1.50) 3.19 (0.80) 3.41 (1.58) 3.27 (0.77)§§ 3.57 (1.54)
Summary performance score (0 to 12 score, 12  best) 10.2 (2.0)## 9.2 (2.9) 10.6 (2.1)*** 10.0 (2.6) 10.3 (2.1)††† 9.5 (2.8)
Values are expressed as mean (SD) unless otherwise indicated. Superscripts indicate p values for comparisons between statin users and statin non-users within each of the three groups: PAD, non-PAD, and all participants. *p  0.001,
†p  0.033, ‡p  0.029, §p  0.0001, p  0.002, ¶p  0.0002, #p  0.019, **p  0.022, ††p  0.043, ‡‡p  0.008, §§p  0.009,  p  0.012, ¶¶p  0.003, ##p  0.0003, ***p  0.090, †††p  0.0005.
HDL  high-density lipoprotein; PAD  peripheral arterial disease.
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Statins and Functional Decline March 7, 2006:998–1004AD participants had an ABI 1.30 and three had an ABI
1.40.
Adjusting for age, race, gender, comorbidities, education,
ealth insurance, total cholesterol/HDL level, and the
ime-dependent variables BMI, pack-years of smoking, leg
ymptoms, immediately previous year functioning, statin
se/non-use, ABI, and change in ABI (Table 2), PAD
articipants on statins had significantly less annual func-
ional decline in usual-pace walking velocity (p  0.013)
nd fastest-pace walking velocity (p  0.006) when com-
ared with PAD participants not taking statins. In these
djusted analyses, PAD participants on statins had less
nnual decline in 6-min walk performance (p  0.088) and
he summary performance score (p  0.067).
Among patients with PAD who were on statins for the
ntire follow-up period and attended all three follow-up
isits, the average time to walk 4 m at a usual pace increased
y a total of 0.71 s (4.53 s at baseline and 5.24 s at three-year
ollow-up) as compared with an increase of 1.74 s (5.20 s at
aseline and 6.94 s at three-year follow-up) in those PAD
atients who never used statins over the three-year
ollow-up period. The results were similar for total time to
alk 4 m rapidly, with increases of 0.39 s for PAD patients
lways on statins (3.29 and 3.68 s at baseline and three-year
ollow-up, respectively) and 1.07 s for PAD patients who
ever took statins (3.77 and 4.84 s, respectively).
Among participants with PAD, results shown in Table 2
ere attenuated slightly when analyses were repeated with
dditional adjustment for hsCRP. For the normal-pace 4-m
alking velocity, average annual changes were 0.006 versus
0.017 m/s/year, p 0.037, after additional adjustment for
sCRP. For fast-paced 4-m walking velocity, average an-
ual changes were 0.002 versus 0.032 m/s/year, p 
.011, after additional adjustment for hsCRP. Additional
djustment for other cardiovascular medication use (aspirin,
eta-blockers, and angiotensin-converting enzyme inhibi-
ors) did not substantially affect our results.
We found no significant associations between statin use
nd functional decline among participants without PAD
Table 2).
ISCUSSION
mong people with PAD, statin users had less average
nnual functional decline compared with statin non-users
ver three years of follow-up, adjusting for a number of
nown and potential confounders. Among people without
AD, we observed no significant associations between statin
se and functional decline.
We previously reported that people with PAD taking
tatins have better lower-extremity functioning than non-
tatin users in cross-sectional analyses (9). Subsequently,
hree placebo-controlled randomized trials evaluated statin
se in PAD patients with intermittent claudication. Of
hese, two trials showed significant improvements in pain-
ree treadmill walking time, but no significant improvement Ta
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March 7, 2006:998–1004 Statins and Functional Declinen maximum treadmill walking distance (10,11). The third
rial showed significant improvements in both pain-free and
aximal treadmill walking distance among PAD partici-
ants randomized to simvastatin as compared with placebo
12). Based on the mixed results from these three trials, the
ssociation between statin therapy and functional outcomes
n people with PAD is still unclear.
Our study differed in several important ways from these
revious clinical trials of statin use in patients with PAD.
irst, whereas previous studies assessed the effects of statin
se on walking impairment in PAD patients with intermit-
ent claudication, we included PAD participants with and
ithout classic symptoms of intermittent claudication. Pre-
ious study shows that most men and women with PAD do
ot have classic symptoms of intermittent claudication
31,32). To our knowledge, no other studies have prospec-
ively assessed associations between statin use and functional
ecline in PAD patients with and without classical inter-
ittent claudication. Second, the three-year follow-up in
he study reported here is longer than the duration of
ollow-up in the clinical trials of statin use in PAD. Third,
ur study simultaneously examined associations between
tatin use and functional decline in participants without
AD. Fourth, functional assessments reported here in-
luded measures other than walking endurance, such as
sual and fastest-pace walking speed over 4 m. Finally, the
unctional outcomes assessed and reported here may be
ore relevant to real-world functioning than treadmill
erformance (24–27,33–36). For example, available data
uggest that the six-minute walk test may be a better
easure of walking endurance in the community than
readmill performance in older populations (33–36). Usual
alking speed and the summary performance score have
een shown to predict risk of future mobility loss, nursing
ome placement, disability in activities of daily living, and
ortality in community-dwelling older men and women
24–27). Thus, 4-m walking velocity and the summary
erformance score are clinically meaningful outcome mea-
ures that are relevant for assessing risk of future mobility
oss, nursing home placement, and other important func-
ional outcome measures.
Studies examining biochemical markers of inflammation
n statin users suggest that the anti-inflammatory effects of
tatins are most pronounced over the initial six weeks of use
nd may level off somewhat over ensuing months (37,38).
ecause participants in this report were likely to have been
n statins for more than six weeks, our findings may
nderestimate the full magnitude of the effect of statin use
n functional decline in PAD participants if attenuation of
nflammation immediately after statins are prescribed is
artly responsible for our observed findings regarding statin
se and functional decline.
Several potential mechanisms may account for the asso-
iations observed between statin use and functional decline
n people with PAD. First, regression of arterial plaque may
e responsible for these associations. However, statins haveeen shown to have only a modest effect on arterial plaque
egression (39), and our findings were independent of the
BI level. Secondly, anti-inflammatory effects of statins
ay explain the association of statin use with less functional
ecline. Systemic inflammation may contribute to sarcope-
ia, an age-related reduction in muscle strength and mass
40–42). Impairments in muscle mass and function may
ontribute to a causal pathway between inflammation and
unctional decline (42). Consistent with this hypothesis, our
ndings were attenuated slightly after additional adjustment
or hsCRP, a systemic inflammatory marker. Lastly, recent
tudies show that statins improve endothelial function in
eripheral arteries (43).
Our study does not allow us to ascertain why statin use
as associated with significantly less functional decline in
-m walking velocity but not in six-minute walk perfor-
ance. However, mechanisms by which statins might
ontribute to less functional decline, such as improved
ndothelial function, may be more important for walking
peed over short distances than walking endurance. Alter-
atively, anti-inflammatory effects of statins may affect type
I (fast-twitch) muscle fibers to a greater degree than type I
slow-twitch) muscle fibers. Further study is necessary to
etermine the mechanisms by which statin use is associated
ith less functional decline in PAD.
Our study has some limitations. First, our study was not
randomized placebo-controlled clinical trial. Second, we
id not have data on medication adherence. It is possible
hat our results may underestimate the effects of statins if all
f the participants were not adherent. Third, statin dosage
nformation was not available, and therefore was not con-
idered in our analyses. We also did not have information on
uration of statin use. In addition, we cannot rule out the
ossibility that positive associations between statin use and
unctioning are attributable to unmeasured confounders
ssociated with better medical care, healthier lifestyle, or
igher socioeconomic status that we could not fully adjust
or in our analyses.
In conclusion, statin use was associated with less annual
ecline in walking speed among patients with PAD, inde-
endent of cholesterol level and other confounders. Further
tudy is needed to determine the mechanisms of findings
eported here. Further study is also needed to determine
hether higher doses of statins are associated with less
unctional decline than lower doses of statins among people
ith PAD.
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